Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented...
November 20 2018 - 7:00AM
Clinical data from a long-term safety study of pharmaceutical-grade
cannabidiol (CBD) oral solution as an investigational treatment for
refractory pediatric epilepsy will be presented on Dec. 3 at the
2018 American Epilepsy Society (AES) annual meeting in New Orleans.
The product candidate evaluated in the study is from INSYS
Therapeutics, Inc. (NASDAQ: INSY), a leader in the development,
manufacture and commercialization of pharmaceutical cannabinoids
and spray technology.
The AES poster presentation on this multicenter, open-label,
flexible-dose study (INS011-14-030) is titled “Long-Term Safety of
Pharmaceutical Cannabidiol Oral Solution as Adjunctive Treatment
for Pediatric Patients with Treatment-Resistant Epilepsy.” The
presentation will be made by James W. Wheless, M.D., professor and
chief of pediatric neurology at the University of Tennessee Health
Science Center in Memphis, where he directs the Neuroscience
Institute & Le Bonheur Comprehensive Epilepsy at Le Bonheur
Children’s Hospital and holds the Le Bonheur Chair in Pediatric
Neurology.
“We look forward to presenting the long-term safety data of our
CBD,” said Ahmed Elkashef, M.D., vice president of clinical
development for INSYS Therapeutics. “These data will inform us and
the scientific community as we continue our development programs
and provide investigational CBD through the expanded access
program.”
Other clinical research on CBD from INSYS includes three ongoing
company-sponsored trials: childhood absence epilepsy (Phase 2),
infantile spasms (Phase 3) and Prader-Willi syndrome (Phase 2).
Results from the Phase 2 trial in childhood absence epilepsy are
expected soon, pending completion of enrollment. All three trials
are actively enrolling patients.
In addition, INSYS has formed collaborative research
partnerships with leading academic institutions to advance the
medical science of pharmaceutical cannabinoids in other disease
states, including autism, early psychosis and anxiety in anorexia
nervosa with the University of California San Diego’s Center for
Medicinal Cannabis Research, and cocaine addiction with the
University of Montreal and the Canadian Institutes of Health
Research.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that
develops and commercializes innovative drugs and novel drug
delivery systems of therapeutic molecules that improve patients’
quality of life. Using proprietary spray technology and
capabilities to develop pharmaceutical cannabinoids, INSYS is
developing a pipeline of products intended to address unmet medical
needs and the clinical shortcomings of existing commercial
products. INSYS is committed to developing medications for
potentially treating anaphylaxis, epilepsy, Prader-Willi syndrome,
opioid addiction and overdose, and other disease areas with a
significant unmet need.
Forward-Looking Statements
This news release contains forward-looking statements based on
management’s expectations and assumptions as of the date of this
news release. Actual results may differ materially from those in
these forward-looking statements as a result of various factors,
many of which are beyond our control. These factors include, but
are not limited to, risks described in our filings with the United
States Securities and Exchange Commission, including those
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the year ended Dec. 31, 2017 and subsequent updates
that may occur in our Quarterly Reports on Form 10-Q.
Forward-looking statements speak only as of the date of this news
release, and we undertake no obligation to publicly update or
revise these statements, except as may be required by law.
CONTACT: |
Corporate
Communications |
Investor
Relations |
|
|
Joe
McGrath |
Jackie
Marcus or Chris Hodges |
|
|
INSYS
Therapeutics |
Alpha IR
Group |
|
|
480-500-3101 |
312-445-2870 |
|
|
jmcgrath@insysrx.com |
INSY@alpha-ir.com |
|
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Mar 2024 to Apr 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2023 to Apr 2024